Andersen-Tawil syndrome (ATS) is an ion channelopathy with variable penetrance for the triad of periodic paralysis, arrhythmia, and dysmorphia. Dominant-negative mutations of KCNJ2 encoding the Kir2.1 potassium channel subunit are found in 60% of ATS families. As with most channelopathies, episodic attacks in ATS are frequently triggered by environmental stresses: exercise for periodic paralysis or stress with adrenergic stimulation for arrhythmia. Fluctuations in K+, either low or high, are potent triggers for attacks of weakness in other variants of periodic paralysis (hypokalemic periodic paralysis or hyperkalemic periodic paralysis). For ATS, the [K+] dependence is less clear; with reports describing weakness in high-K+ or low-K+. Patient trials with controlled K+ challenges are not possible, due to arrhythmias. We have developed two mouse models (genetic and pharmacologic) with reduced Kir currents, to address the question of K+-sensitive loss of force. These animal models and computational simulations both show K+-dependent weakness occurs only when Kir current is <30% of wildtype. As the Kir deficit becomes more severe, the phenotype shifts from high-K+-induced weakness to a combination where either high-K+ or low-K+ triggers weakness. A K+ channel agonist, retigabine, protects muscle from K+-sensitive weakness in our mouse models of the skeletal muscle involvement in ATS.
Keywords: Kir2.1; periodic paralysis; potassium channel; skeletal muscle.